Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Safety
  4. Fast Track Articles
  5. Fast Track Article
image of Opioid Use Disorders: Prevention, Diagnosis, and Treatment Strategies to Mitigate Addiction Risks

Abstract

Opioid Use Disorder (OUD) is defined by the persistent use of opioids despite adverse consequences. It is associated with increased mortality and a variety of mental and general medical comorbidities. Risk factors include younger age, male sex, lower educational attainment, lower income, and psychiatric disorders, such as other substance use disorders and mood disorders. Genetics also play a role in susceptibility to opioid use disorders. Long-term self-efficacy in opioid use for non-medical purposes suggests irreversible opioid use disorders.

To evaluate the current understanding of opioid use disorders, the limitations in existing treatment approaches were examined, and strategies to improve outcomes through expanded treatment access and personalized care interventions were identified.

An analysis was carried out regarding the role of existing pharmacological treatments, barriers within the care cascade, and potential advancements in healthcare delivery and innovation was carried out to address opioid use disorders. A comprehensive review of the literature was conducted by searching electronic databases (., PubMed, Scopus) for articles published over the past 20-25 years. Relevant studies were selected based on predefined inclusion criteria, focusing on OUD risk factors, pharmacological treatments, barriers in the care cascade, and strategies for improving care. The selection process prioritized systematic reviews, clinical trials, and key guidelines.

Although medications for opioid use disorders are effective, their impact is hindered by systemic issues at multiple levels of care. Addressing these challenges requires comprehensive efforts, including professional training, innovative treatments, and healthcare reforms to expand access and personalize care.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863357891250213094516
2025-02-20
2025-06-26

  • From This Site

    /content/journals/cds/10.2174/0115748863357891250213094516
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Portenoy R.K. Payne R. Passik S.K. Lowinson J.H. Ruz P. Millman R.B. Langrod J.G. Acute and Chronic Pain Substance Abuse: A Comprehensive Textbook Lippincott Williams and Wilkins 2004 863 904
    [Google Scholar]
  2. Field M.J. Cassel C.K. Approaching death: Improving care at the end of life. Washington, DC National Academy Press 1997
    [Google Scholar]
  3. Schnoll S.H. Weaver M.F. Addiction and pain. Am. J. Addict. 2003 12 2 S27 S35 10.1080/10550490390210218 12857661
    [Google Scholar]
  4. Portenoy R.K. Lesage P. Management of cancer pain. Lancet 1999 353 9165 1695 1700 10.1016/S0140‑6736(99)01310‑0 10335806
    [Google Scholar]
  5. Breitbart W. Passik S. McDonald M.V. Rosenfeld B. Smith M. Kaim M. Funesti-Esch J. Patient-related barriers to pain management in ambulatory AIDS patients. Pain 1998 76 1 9 16 10.1016/S0304‑3959(98)00018‑9 9696454
    [Google Scholar]
  6. Smith W.R. Penberthy L.T. Bovbjerg V.E. McClish D.K. Roberts J.D. Dahman B. Aisiku I.P. Levenson J.L. Roseff S.D. Daily assessment of pain in adults with sickle cell disease. Ann. Intern. Med. 2008 148 2 94 101 10.7326/0003‑4819‑148‑2‑200801150‑00004 18195334
    [Google Scholar]
  7. Ballantyne J.C. LaForge S.K. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007 129 3 235 255 10.1016/j.pain.2007.03.028 17482363
    [Google Scholar]
  8. Streltzer J. Johansen L. Prescription drug dependence and evolving beliefs about chronic pain management. Am. J. Psychiatry 2006 163 4 594 598 10.1176/ajp.2006.163.4.594 16585432
    [Google Scholar]
  9. Streltzer J. Kosten T.R. Methadone maintenance therapy and chronic pain. JAMA 2003 290 18 2403 2404 10.1001/jama.290.18.2403‑a 14612466
    [Google Scholar]
  10. Vallersnes O.M. Jacobsen D. Ekeberg Ø. Brekke M. Mortality, morbidity and follow-up after acute poisoning by substances of abuse: A prospective observational cohort study. Scand. J. Public Health 2019 47 4 452 461 10.1177/1403494818779955 29886813
    [Google Scholar]
  11. Gamble J. O’Lawrence H. An overview of the efficacy of the 12-step group therapy for substance abuse treatment. J. Health Hum. Serv. Adm. 2016 39 1 141 159 10.1177/107937391603900108 27483978
    [Google Scholar]
  12. Gondwal R. Avinash P. Victor R. Dharuvika The missing link between opioid use disorder and seizures during opioid withdrawal: A case series from North India. Indian J. Psychol. Med. 2024 46 1 81 84 10.1177/02537176231167080 38524948
    [Google Scholar]
  13. Bhawalkar J. Saraf A. Malik M.M. The opioid crisis, preventing and managing substance abuse in India: A systematic review. Cureus 2024 16 10 e70600 10.7759/cureus.70600 39483538
    [Google Scholar]
  14. Brat G.A. Agniel D. Beam A. Yorkgitis B. Bicket M. Homer M. Fox K.P. Knecht D.B. McMahill-Walraven C.N. Palmer N. Kohane I. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: Retrospective cohort study. BMJ 2018 360 j5790 10.1136/bmj.j5790 29343479
    [Google Scholar]
  15. American Psychiatric Association Opioid use disorder diagnostic criteria. Available from:http://pcssmat.org/wp-content/uploads/2014/02/5B-DSM-5-Opioid-Use-Disorder-Diagnostic-Criteria.pdf
  16. Dick D.M. Agrawal A. The genetics of alcohol and other drug dependence. Alcohol Res. Health 2008 31 2 111 118 23584813
    [Google Scholar]
  17. Goodman C.C. Snyder T.E.K. Differential Diagnosis for Physical Therapists: Screening for Referral. 5th ed St. Louis, MO Saunders/Elsevier 2013 49 51
    [Google Scholar]
  18. Sharma B. Bruner A. Barnett G. Fishman M. Opioid use disorders. Child Adolesc. Psychiatr. Clin. N. Am. 2016 25 3 473 487 10.1016/j.chc.2016.03.002 27338968
    [Google Scholar]
  19. Mistry C. Bawor M. Desai D. Marsh D. Samaan Z. Genetics of opioid dependence: A review of the genetic contribution to opioid dependence. Curr. Psychiatry Rev. 2014 10 2 156 167 10.2174/1573400510666140320000928 25242908
    [Google Scholar]
  20. Theisen K. Jacobs B. Macleod L. Davies B. The United States opioid epidemic: A review of the surgeon’s contribution to it and health policy initiatives. BJU Int. 2018 122 5 754 759 10.1111/bju.14446 29896932
    [Google Scholar]
  21. Blum K. Jacobs W. Modestino E.J. DiNubile N. Baron D. McLaughlin T. Siwicki D. Elman I. Moran M. Braverman E.R. Thanos P.K. Badgaiyan R.D. Insurance companies fighting the peer review empire without any validity: The case for addiction and pain modalities in the face of an American Drug Epidemic. SEJ Surg Pain 2018 1 1 1 11 29911684
    [Google Scholar]
  22. Jones C.M. Einstein E.B. Compton W.M. Changes in Synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016. JAMA 2018 319 17 1819 1821 10.1001/jama.2018.2844 29715347
    [Google Scholar]
  23. Højsted J. Sjøgren P. Addiction to opioids in chronic pain patients: A literature review. Eur. J. Pain 2007 11 5 490 518 10.1016/j.ejpain.2006.08.004 17070082
    [Google Scholar]
  24. Rosenbloom J.M. Burns S.M. Kim E. August D.A. Ortiz V.E. Houle T.T. Race/ethnicity and sex and opioid administration in the emergency room. Anesth. Analg. 2019 128 5 1005 1012 10.1213/ANE.0000000000003517 29863607
    [Google Scholar]
  25. Bernstein M.H. McSheffrey S.N. van den Berg J.J. Vela J.E. Stein L.A.R. Roberts M.B. Martin R.A. Clarke J.G. The association between impulsivity and alcohol/drug use among prison inmates. Addict. Behav. 2015 42 140 143 10.1016/j.addbeh.2014.11.016 25462662
    [Google Scholar]
  26. Kollas C.D. Ruiz K. Laughlin A. Effectiveness of long-term opioid therapy for chronic pain in an outpatient palliative medicine clinic. J. Palliat. Med. 2024 27 1 31 38 10.1089/jpm.2023.0251 37552851
    [Google Scholar]
  27. Kissin I. Long-term opioid treatment of chronic nonmalignant pain: Unproven efficacy and neglected safety? J. Pain Res. 2013 6 513 529 10.2147/JPR.S47182 23874119
    [Google Scholar]
  28. Bloodworth D. Opioids in the treatment of chronic pain: Legal framework and therapeutic indications and limitations. Phys. Med. Rehabil. Clin. N. Am. 2006 17 2 355 379 10.1016/j.pmr.2005.12.001 16616272
    [Google Scholar]
  29. Pinkerton R. Hardy J.R. Opioid addiction and misuse in adult and adolescent patients with cancer. Intern. Med. J. 2017 47 6 632 636 10.1111/imj.13449 28580748
    [Google Scholar]
  30. Camí J. Farré M. Drug addiction. N. Engl. J. Med. 2003 349 10 975 986 10.1056/NEJMra023160 12954747
    [Google Scholar]
  31. Reisine T. Pasternak G. Opioid analgesics and antagonists. Pharmacological Basis of Therapeutics, 9th. Hardman J.G. Gilman A. Limbird L.E. New York McGraw-Hill 1996 521
    [Google Scholar]
  32. Way W.L. Way E.L. Opioid analgesics and antagonists. Basic and Clinical pharmacology. Katzung B.G. Norwalk, CT Appleton & Lange 1989 368
    [Google Scholar]
  33. Watson S.J. Akil H. Khachaturian H. Opioid systems: Anatomical, physiological and clinical perspectives. Opioids Past, Present and Future. Hughes J. Collier H.O. Rance M.J. Tyers M.B. London Taylor & Francis 1984 145
    [Google Scholar]
  34. Sporer K.A. Acute heroin overdose. Ann. Intern. Med. 1999 130 7 584 590 10.7326/0003‑4819‑130‑7‑199904060‑00019 10189329
    [Google Scholar]
  35. Zhao J. Cai S. Zhang L. Rao Y. Kang X. Feng Z. Progress, challenges, and prospects of research on the effect of gene polymorphisms on adverse reactions to opioids. Pain Ther. 2022 11 2 395 409 10.1007/s40122‑022‑00374‑0 35429333
    [Google Scholar]
  36. Yang Y. Zhang X. Wang Y. Xi H. Xu M. Zheng L. Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes. Front. Pharmacol. 2024 15 1342515 10.3389/fphar.2024.1342515 38756374
    [Google Scholar]
  37. McNeely J. Cleland C.M. Strauss S.M. Palamar J.J. Rotrosen J. Saitz R. Validation of self-administered single-item screening questions (SISQs) for unhealthy alcohol and drug use in primary care patients. J. Gen. Intern. Med. 2015 30 12 1757 1764 10.1007/s11606‑015‑3391‑6 25986138
    [Google Scholar]
  38. John W.S. Zhu H. Mannelli P. Schwartz R.P. Subramaniam G.A. Wu L.T. Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. Drug Alcohol Depend. 2018 187 79 87 10.1016/j.drugalcdep.2018.01.035 29635217
    [Google Scholar]
  39. Ober A.J. Watkins K.E. McCullough C.M. Setodji C.M. Osilla K. Hunter S.B. Patient predictors of substance use disorder treatment initiation in primary care. J. Subst. Abuse Treat. 2018 90 64 72 10.1016/j.jsat.2018.04.004 29866385
    [Google Scholar]
  40. Johnson R. Strain E.C. Amass L. Buprenorphine: How to use it right. Drug Alcohol Depend. 2003 70 2 Suppl. S59 S77 10.1016/S0376‑8716(03)00060‑7 12738351
    [Google Scholar]
  41. LeFevre M.L. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2014 161 1 58 66 10.7326/M14‑1018 24863637
    [Google Scholar]
  42. Moyer V.A. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2013 159 5 349 357 10.7326/0003‑4819‑159‑5‑201309030‑00672 23798026
    [Google Scholar]
  43. Meyerhoff D.J. Structural neuroimaging in polysubstance users. Curr. Opin. Behav. Sci. 2017 13 13 18 10.1016/j.cobeha.2016.07.006 28094824
    [Google Scholar]
  44. Dowell D. Haegerich T.M. Chou R. CDC Guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm. Rep. 2016 65 1 1 49 10.15585/mmwr.rr6501e1 26987082
    [Google Scholar]
  45. Our commitment to fight opioid abuse. Available from: https://www.cvshealth.com/impact/healthy-community/our-opioid-response.html#:~:text=A%20commitment%20from%20our%20Company,important%20priority%20of%20CVS%20Health.
  46. Combat opioid abuse | Walgreens 2018 Available from: https://www.walgreens.com/topic/pharmacy/combat_opioid_abuse.jsphttps://www.walgreens.com/topic/pharmacy/combat_opioid_abuse.jsp
  47. Prevent opioid use disorder: Drug overdose. 2018 Available from: www.cdc.gov 2018
  48. Naloxone. Human Metabolome Database: Version 4.0. 2017 Available from: https://hmdb.ca/metabolites/HMDB0015314
  49. Naloxone for treatment of opioid overdose Available from: https://www.bexar.org/DocumentCenter/View/13675/Naloxone-for-Treatment-of-Opioid-Overdose-Breifing-Material-PDF
  50. Wheeler E. Jones T.S. Gilbert M.K. Opioid overdose prevention programs providing Naloxone to Laypersons - United States. MMWR Morb. Mortal. Wkly. Rep. 64 23 631 26086633
    [Google Scholar]
  51. Childs R. Law enforcement and naloxone utilization in the United States. 2015 Available from: https://bjatta.bja.ojp.gov/naloxone/law-enforcement-and-naloxone-utilization-united-states
  52. Case studies: Standing orders Available from: https://www.opensocietyfoundations.org/voices/training-drug-users-and-bystanders-treat-overdose-saves-lives
    [Google Scholar]
  53. Schuckit M.A. Treatment of opioid-use disorders. N. Engl. J. Med. 2016 375 4 357 368 10.1056/NEJMra1604339 27464203
    [Google Scholar]
  54. Madras B.K. The president’s commission on combating drug addiction and the opioid crisis: Origins and recommendations. Clin. Pharmacol. Ther. 2018 103 6 943 945 10.1002/cpt.1050 29570781
    [Google Scholar]
  55. Naloxone opioid overdose reversal medication Available from: https://www.cvshealth.com/news/community/naloxone-opioid-overdose-reversal-medication.html
  56. Fals-Stewart W. O’Farrell T.J. Behavioral family counseling and naltrexone for male opioid-dependent patients. J. Consult. Clin. Psychol. 2003 71 3 432 442 10.1037/0022‑006X.71.3.432 12795568
    [Google Scholar]
  57. Gossop M. Stewart D. Marsden J. Attendance at Narcotics Anonymous and Alcoholics Anonymous meetings, frequency of attendance and substance use outcomes after residential treatment for drug dependence: A 5‐year follow‐up study. Addiction 2008 103 1 119 125 10.1111/j.1360‑0443.2007.02050.x 18028521
    [Google Scholar]
  58. Galanter M. Combining medically assisted treatment and Twelve-Step programming: A perspective and review. Am. J. Drug Alcohol Abuse 2018 44 2 151 159 10.1080/00952990.2017.1306747 28387530
    [Google Scholar]
  59. Fals-Stewart W. O’Farrell T.J. Birchler G.R. Behavioral couples therapy for substance abuse: Rationale, methods, and findings. Sci. Pract. Perspect. 2004 2 2 30 41 10.1151/spp042230 18552731
    [Google Scholar]
  60. Meyers R.J. Miller W.R. Hill D.E. Tonigan J.S. Community reinforcement and family training (CRAFT): Engaging unmotivated drug users in treatment. J. Subst. Abuse 1998 10 3 291 308 10.1016/S0899‑3289(99)00003‑6 10689661
    [Google Scholar]
  61. Moberg K. The role of managed care professionals and pharmacists in combating opioid abuse. Am. J. Manag. Care 2018 24 10 Suppl. S215 S223 29851451
    [Google Scholar]
  62. Szalavitz M. Rigg K.K. The curious (Dis)Connection between the opioid epidemic and crime. Subst. Use Misuse 2017 52 14 1927 1931 10.1080/10826084.2017.1376685 28952839
    [Google Scholar]
  63. Fiellin D.A. Barry D.T. Sullivan L.E. Cutter C.J. Moore B.A. O’Connor P.G. Schottenfeld R.S. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am. J. Med. 2013 126 1 74.e11 74.e17 10.1016/j.amjmed.2012.07.005 23260506
    [Google Scholar]
  64. Strain E.C. Stitzer M.L. Liebson I.A. Bigelow G.E. Dose-response effects of methadone in the treatment of opioid dependence. Ann. Intern. Med. 1993 119 1 23 27 10.7326/0003‑4819‑119‑1‑199307010‑00004 8498759
    [Google Scholar]
  65. Kampman K. Jarvis M. American Society of Addiction Medicine (ASAM) National Practice guideline for the use of medications in the treatment of addiction involving opioid use. J. Addict. Med. 2015 9 5 358 367 10.1097/ADM.0000000000000166 26406300
    [Google Scholar]
  66. Mancher M. Leshner I. National Academies of Sciences Health and Medicine Division Medications for Opioid Use Disorder Save Lives National Academies Press (US) Washington 2019
    [Google Scholar]
  67. Lee J.D. Nunes E.V. Jr Novo P. Bachrach K. Bailey G.L. Bhatt S. Farkas S. Fishman M. Gauthier P. Hodgkins C.C. King J. Lindblad R. Liu D. Matthews A.G. May J. Peavy K.M. Ross S. Salazar D. Schkolnik P. Shmueli-Blumberg D. Stablein D. Subramaniam G. Rotrosen J. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial. Lancet 2018 391 10118 309 318 10.1016/S0140‑6736(17)32812‑X 29150198
    [Google Scholar]
  68. Tanum L. Solli K.K. Latif Z.E. Effectiveness of injectable extended-release Naltrexone vs Daily Buprenorphine-Naloxone for opioid dependence: A Randomized clinical noninferiority trial. JAMA Psychiatry 2018 75 5 530 29049469
    [Google Scholar]
  69. Gibson A. Degenhardt L. Mattick R.P. Ali R. White J. O’Brien S. Exposure to opioid maintenance treatment reduces long‐term mortality. Addiction 2008 103 3 462 468 10.1111/j.1360‑0443.2007.02090.x 18190664
    [Google Scholar]
  70. Faggiano F. Vigna-Taglianti F. Versino E. Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Libr. 2003 3 CD002208 10.1002/14651858.CD002208 12917925
    [Google Scholar]
  71. Johnson R.E. Chutuape M.A. Strain E.C. Walsh S.L. Stitzer M.L. Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 2000 343 18 1290 1297 10.1056/NEJM200011023431802 11058673
    [Google Scholar]
  72. Kakko J. Svanborg K.D. Kreek M.J. Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 2003 361 9358 662 668 10.1016/S0140‑6736(03)12600‑1 12606177
    [Google Scholar]
  73. Mattick R.P. Kimber J. Breen C. Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2004 3 CD002207 10.1002/14651858.CD002207.pub2 15266465
    [Google Scholar]
  74. Ma J. Bao Y.P. Wang R.J. Su M.F. Liu M.X. Li J.Q. Degenhardt L. Farrell M. Blow F.C. Ilgen M. Shi J. Lu L. Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis. Mol. Psychiatry 2019 24 12 1868 1883 10.1038/s41380‑018‑0094‑5 29934549
    [Google Scholar]
  75. Kakko J. Heilig M. Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: Comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug. Alcohol. Depend. 2008 96 1-2 69 78 10.1016/j.drugalcdep.2008.01.025 18355989
    [Google Scholar]
  76. Senay E.C. Dorus W. Goldberg F. Thornton W. Withdrawal from methadone maintenance. Rate of withdrawal and expectation. Arch. Gen. Psychiatry 1977 34 3 361 367 10.1001/archpsyc.1977.01770150119014 843188
    [Google Scholar]
  77. Minozzi S. Amato L. Vecchi S. Davoli M. Kirchmayer U. Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. 2011 2 CD001333 21328250
    [Google Scholar]
  78. Edelman E.J. Oldfield B.J. Tetrault J.M. Office-based addiction treatment in primary care. Med. Clin. North Am. 2018 102 4 635 652 10.1016/j.mcna.2018.02.007 29933820
    [Google Scholar]
  79. Fudala P.J. Bridge T.P. Herbert S. Williford W.O. Chiang C.N. Jones K. Collins J. Raisch D. Casadonte P. Goldsmith R.J. Ling W. Malkerneker U. McNicholas L. Renner J. Stine S. Tusel D. Buprenorphine/Naloxone Collaborative Study Group Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 2003 349 10 949 958 10.1056/NEJMoa022164 12954743
    [Google Scholar]
  80. Rahimi-Movaghar A. Gholami J. Amato L. Hoseinie L. Yousefi-Nooraie R. Amin-Esmaeili M. Pharmacological therapies for management of opium withdrawal. Cochrane Libr. 2018 2018 6 CD007522 10.1002/14651858.CD007522.pub2
    [Google Scholar]
  81. Wakeman S.E. Harm reduction approaches for opioid use disorder. Treating Opioid Addiction. Chapter 8 Kelly J.F. Wakeman S. Springer Science Press 2019 10.1007/978‑3‑030‑16257‑3_8
    [Google Scholar]
  82. Coffin P.O. Behar E. Rowe C. Santos G.M. Coffa D. Bald M. Vittinghoff E. Nonrandomized Intervention study of Naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann. Intern. Med. 2016 165 4 245 252 10.7326/M15‑2771 27366987
    [Google Scholar]
  83. Phillips J.k. Ford M.A. Bonnie R.J. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington (DC) Academies Press 2017
    [Google Scholar]
  84. Sordo L. Barrio G. Bravo M.J. Indave B.I. Degenhardt L. Wiessing L. Ferri M. Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ 2017 357 j1550 10.1136/bmj.j1550 28446428
    [Google Scholar]
  85. Fullerton C.A. Kim M. Thomas C.P. Lyman D.R. Montejano L.B. Dougherty R.H. Daniels A.S. Ghose S.S. Delphin-Rittmon M.E. Medication-assisted treatment with methadone: Assessing the evidence. Psychiatr. Serv. 2014 65 2 146 157 10.1176/appi.ps.201300235 24248468
    [Google Scholar]
  86. Sorensen J.L. Copeland A.L. Drug abuse treatment as an HIV prevention strategy: A review. Drug Alcohol Depend. 2000 59 1 17 31 10.1016/S0376‑8716(99)00104‑0 10706972
    [Google Scholar]
  87. Gandhi D.H. Jaffe J.H. McNary S. Kavanagh G.J. Hayes M. Currens M. Short‐term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction 2003 98 4 453 462 10.1046/j.1360‑0443.2003.00334.x 12653815
    [Google Scholar]
  88. Bond C. LaForge K.S. Tian M. Melia D. Zhang S. Borg L. Gong J. Schluger J. Strong J.A. Leal S.M. Tischfield J.A. Kreek M.J. Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: Possible implications for opiate addiction. Proc. Natl. Acad. Sci. USA 1998 95 16 9608 9613 10.1073/pnas.95.16.9608 9689128
    [Google Scholar]
  89. Bart G. Heilig M. LaForge K.S. Pollak L. Leal S.M. Ott J. Kreek M.J. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry 2004 9 6 547 549 10.1038/sj.mp.4001504 15037869
    [Google Scholar]
  90. Bart G. Kreek M.J. Ott J. LaForge K.S. Proudnikov D. Pollak L. Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005 30 2 417 422 10.1038/sj.npp.1300598 15525999
    [Google Scholar]
  91. Wand G. McCaul M. Yang X. Reynolds J. Gotjen D. Lee S. Ali A. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002 26 1 106 114 10.1016/S0893‑133X(01)00294‑9 11751037
    [Google Scholar]
  92. Hernandez-Avila C.A. Wand G. Luo X. Gelernter J. Kranzler H.R. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the μ‐opioid receptor locus (OPRM1). Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2003 118B 1 60 65 10.1002/ajmg.b.10054 12627468
    [Google Scholar]
  93. Ducat E. Ray B. Bart G. Umemura Y. Varon J. Ho A. Kreek M.J. Mu‐opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic–pituitary–adrenal axis adrenocorticotropic hormone stress response to metyrapone. Addict. Biol. 2013 18 2 325 331 10.1111/j.1369‑1600.2011.00313.x 21507151
    [Google Scholar]
  94. Zhang Y Picetti R Butelman ER Ho A Blendy JA Kreek MJ Mouse model of the OPRM1 (A118G) polymorphism: Differential heroin self-administration behavior compared with wild-type mice. Neuropsychopharmacology 2015 40 5 1091 10.1038/npp.2014.286
    [Google Scholar]
  95. Crist R.C. Reiner B.C. Berrettini W.H. A review of opioid addiction genetics. Curr. Opin. Psychol. 2019 27 31 35 10.1016/j.copsyc.2018.07.014 30118972
    [Google Scholar]
  96. Levran O. Peles E. Hamon S. Randesi M. Adelson M. Kreek M.J. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict. Biol. 2013 18 4 709 716 10.1111/j.1369‑1600.2011.00349.x 21790905
    [Google Scholar]
  97. Levran O. O’Hara K. Peles E. Li D. Barral S. Ray B. Borg L. Ott J. Adelson M. Kreek M.J. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum. Mol. Genet. 2008 17 14 2219 2227 10.1093/hmg/ddn122 18424454
    [Google Scholar]
  98. Oertel B.G. Schmidt R. Schneider A. Geisslinger G. Lötsch J. The μ-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet. Genomics 2006 16 9 625 636 10.1097/01.fpc.0000220566.90466.a2 16906017
    [Google Scholar]
  99. Salsitz E.A. Chronic pain, chronic opioid addiction: A complex nexus. J. Med. Toxicol. 2016 12 1 54 57 10.1007/s13181‑015‑0521‑9 26602212
    [Google Scholar]
  100. Juurlink D.N. Dhalla I.A. Dependence and addiction during chronic opioid therapy. J. Med. Toxicol. 2012 8 4 393 399 10.1007/s13181‑012‑0269‑4 23073725
    [Google Scholar]
  101. Rouault M. Nielsen D.A. Ho A. Kreek M.J. Yuferov V. Cell‐specific effects of variants of the 68‐base pair tandem repeat on prodynorphin gene promoter activity. Addict. Biol. 2011 16 2 334 346 10.1111/j.1369‑1600.2010.00248.x 20731629
    [Google Scholar]
  102. Yuferov V. Randesi M. Butelman E.R. van den Brink W. Blanken P. van Ree J.M. Ott J. Kreek M.J. Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use. Neurosci. Lett. 2019 704 100 105 10.1016/j.neulet.2019.03.038 30936032
    [Google Scholar]
  103. Ray R. Doyle G.A. Crowley J.J. Buono R.J. Oslin D.W. Patkar A.A. Mannelli P. DeMaria P.A. Jr O’Brien C.P. Berrettini W.H. A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatr. Genet. 2005 15 4 295 298 10.1097/00041444‑200512000‑00013 16314761
    [Google Scholar]
  104. Williams T.J. LaForge K.S. Gordon D. Bart G. Kellogg S. Ott J. Kreek M.J. GENETIC STUDY: Prodynorphin gene promoter repeat associated with cocaine/alcohol codependence. Addict. Biol. 2007 12 3-4 496 502 10.1111/j.1369‑1600.2007.00069.x 17559549
    [Google Scholar]
  105. Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings. Geneva World Health Organization 2009
    [Google Scholar]
  106. Hser Y.I. Mooney L.J. Saxon A.J. Miotto K. Bell D.S. Zhu Y. Liang D. Huang D. High mortality among patients with opioid use disorder in a large healthcare system. J. Addict. Med. 2017 11 4 315 319 10.1097/ADM.0000000000000312 28426439
    [Google Scholar]
  107. Park K. Otte A. Prevention of opioid abuse and treatment of opioid addiction: Current status and future possibilities. Annu. Rev. Biomed. Eng. 2019 21 1 61 84 10.1146/annurev‑bioeng‑060418‑052155 30786212
    [Google Scholar]
  108. Griffin P.M. Engineering approaches for addressing opioid use disorder in the community. Annu. Rev. Biomed. Eng. 2020 22 1 207 229 10.1146/annurev‑bioeng‑082719‑040832 32255677
    [Google Scholar]
  109. Wang SC Chen YC Lee CH Cheng CM Opioid addiction, genetic susceptibility, and medical treatments: A review. Int. J. Mol. Sci. 2019 20 17 4294 10.3390/ijms20174294 31480739
    [Google Scholar]
  110. Nuamah J. Mehta R. Sasangohar F. Technologies for opioid use disorder management: Mobile app search and scoping review. JMIR Mhealth Uhealth 2020 8 6 e15752 10.2196/15752 32501273
    [Google Scholar]
  111. Rohin MA Baig AA Ridzwan N Abd Hadi N Nanotechnology-based delivery of non-opioid therapy for opioid addiction. Handbook of Nanotechnology in Nutraceuticals CRC Press 2022 149 182 10.1201/9781003244721‑7
    [Google Scholar]
/content/journals/cds/10.2174/0115748863357891250213094516
Loading
Opioid Use Disorders: Prevention, Diagnosis, and Treatment Strategies to Mitigate Addiction Risks
Bentham Science Publishers ; https://doi.org/10.2174/0115748863357891250213094516
/content/journals/cds/10.2174/0115748863357891250213094516
/content/journals/cds/10.2174/0115748863357891250213094516
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: addiction ; morphine receptor ; naltrexone ; Opioid ; buprenorphine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test